Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Medical Device

Sinocare Inc’s Blood Glucose Monitoring System Earns US FDA Approval

Fineline Cube Dec 6, 2023

Sinocare Inc (SHE: 300298), a Chinese medical device company, has announced that it has received...

Company Drug

Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy

Fineline Cube Dec 6, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has received approval from the...

Company Drug

Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038

Fineline Cube Dec 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug

Fineline Cube Dec 6, 2023

Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab

Fineline Cube Dec 6, 2023

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...

Company Drug

China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval

Fineline Cube Dec 6, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment

Fineline Cube Dec 6, 2023

Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a...

Company Medical Device

Sino Medical Secures Market Approval in Taiwan for NC Rockstar Coronary Catheter

Fineline Cube Dec 6, 2023

Sino Medical Sciences Technology Inc. (SHA: 688108) has announced that its NC Rockstar non-compliant coronary...

Company Drug

Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod

Fineline Cube Dec 5, 2023

Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...

Company Drug

Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug

Fineline Cube Dec 5, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...

Company Drug

Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide

Fineline Cube Dec 5, 2023

Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...

Company Drug

Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial

Fineline Cube Dec 5, 2023

Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...

Company

WuXi Biologics Shares Plunge 22% on Slower CDMO Industry Growth and Revenue Shortfall

Fineline Cube Dec 5, 2023

WuXi Biologics (HKG: 2269) experienced a 22% decline in its share price on Monday, December...

Company Deals

Abbisko Therapeutics Strikes Licensing Deal with Merck KGaA for CSF-1R Inhibitor Pimicotinib

Fineline Cube Dec 5, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced a licensing agreement...

Company Deals

Boehringer Ingelheim Partners with Shanghai Handu Pharma to Enhance Oral Medication Delivery

Fineline Cube Dec 5, 2023

Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Shanghai Handu...

Company Deals

Gedeon Richter Acquires Rights to Mithra’s Contraceptive and Menopause Treatments for Chinese Market

Fineline Cube Dec 5, 2023

Gedeon Richter Plc, a Hungarian pharmaceutical company, and Belgium’s Mithra (OTCMKTS: MITPF) have entered into...

Company Deals

Aspen Pharmacare Holdings to Boost China Presence with Full Acquisition of Sandoz’s Subsidiary

Fineline Cube Dec 5, 2023

Aspen Pharmacare Holdings (JSE: APN), a South Africa-based pharmaceutical company, is poised to enhance its...

Company Drug

AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues

Fineline Cube Dec 5, 2023

AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...

Company Deals

Roche Expands Beyond Oncology with USD 2.7 Billion Carmot Therapeutics Acquisition

Fineline Cube Dec 5, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has entered into an agreement to acquire U.S. biotech...

Company Drug

Stem-Cell Startup Xellsmart Earns FDA Orphan Drug Designation for ALS Therapy

Fineline Cube Dec 5, 2023

Xellsmart, a stem-cell startup headquartered in Suzhou, has announced that it has received orphan drug...

Posts pagination

1 … 375 376 377 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.